

Glenmark offers new anti-diabetic FDC medication under brand name Zita D

20 October 2022 | News

First company in India to launch Tenzeligliptin + Dapagliflozin fixed dose combination, for adults with Type 2 Diabetes, having comorbidities

Glenmark Pharmaceuticals has become the first to launch Tenzeligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities.

Marketed under the brand name Zita D; it contains Tenzeligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

Tenzeligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT2i (Sodium glucose co-transporter 2) inhibitor for diabetic patients in the country. While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co-morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark's Zita D is priced at around Rs 14 per tablet for FDC of Tenzeligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Tenzeligliptin 20 mg + Dapagliflozin 10 mg, per day.